

| カタログ番号 | HM818013 | ||||
|---|---|---|---|---|---|
| 種反応性 | Human | ||||
| アプリケーション | ELISA | ||||
| 宿主種 | Mouse | ||||
| クローン性 | Monoclonal | ||||
| アイソタイプ | IgG1 | ||||
| クローンID | MP9 | ||||
| ターゲット | HLAA, Human leukocyte antigen A, HLA class I histocompatibility antigen, A alpha chain, HLA-A | ||||
| エンドトキシンレベル | Please contact with the lab for this information. | ||||
| 純度 | >95% as determined by SDS-PAGE. | ||||
| 精製 | Protein A/G purified from cell culture supernatant. | ||||
| アクセッション番号 | P04439 | ||||
| RRID | Anti-Human HLA-A3 Antibody (MP9) (abinScience Cat# HM818013, RRID:AB_3727814) |
||||
| 形態 | Liquid | ||||
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
||||
| 製品使用情報 |
| ||||
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. | ||||
| 背景 | HLA class I histocompatibility antigen, A alpha chain (HLA-A3) is a ~40 kDa protein. Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme. 1. Fukada, K. et al. (1999) AIDS (London, England) 13, 1413-4. PMID: 10449296 2. Nagata, Y. et al. (2002) Proceedings of the National Academy of Sciences of the United States of America 99, 10629-34. PMID: 12138174 3. Kuzushima, K. et al. (2003) Blood 101, 1460-8. PMID: 12393434 4. Traversari, C. et al. (1992) The Journal of experimental medicine 176, 1453-7. PMID: 1402688 5. Satoh, M. et al. (2005) Vaccine 23, 3783-90. PMID: 15893615 6. Asemissen, AM. et al. (2006) Clinical cancer research : an official journal of the American Association for Cancer Research 12, 7476-82. PMID: 17189421 7. Hadrup, SR. et al. (2009) Nature methods 6, 520-6. PMID: 19543285 8. Matthews, PC. et al. (2011) Journal of immunology (Baltimore, Md. : 1950) 186, 5675-86. PMID: 21498667 9. Shimizu, A. et al. (2013) Scientific reports 3, 3097. PMID: 24192765 10. Quiñones-Parra, S. et al. (2014) Proceedings of the National Academy of Sciences of the United States of America 111, 1049-54. PMID: 24395804 | ||||
| 注意事項 | For research use only. |

SDS-PAGE for Anti-Human HLA-A3 Antibody (MP9)


+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский